Purpose: To report outcomes of transarterial radioembolization (TARE) using glass microspheres for the treatment of mixed hepatocellular-cholangiocarcinoma (HCC-CC) in a propensity-matched study. Material and Methods: Between 2013 and 2019, 10 consecutive patients with histologically confirmed HCC-CC received TARE of a targeted territory using glass microspheres as a primary initial treatment. Baseline demographics in addition to tumor distribution, Child Pugh score, and BCLC were recorded. Tumor response was assessed according to modified RECIST criteria. The HCC-CC cohort was matched to the HCC cohort, and objective response and survival analysis was performed. Results: In the HCC-CC cohort, patients had a 70% objective response rate (ORR), and in the HCC cohort, patients had a 90% ORR after matching (p = 0.54). The median overall survival (OS) for HCC patients was 12.3 months (95% CI: 6.0–17.4 months) in the matched population, and for HCC-CC patients, the median OS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.98). The median progression-free survival (PFS) for HCC patients was 11.6 months (95% CI: 2.53–19.3 months) in the matched population, and for HCC-CC patients, the median PFS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.94). The median transplant-free survival (TFS) for HCC patients was 12.3 months (95% CI: 6.0–17.4 months) in the matched population, and for HCC-CC patients, the median TFS was 15.2 months (95% CI: 2.7–20.2 months) (p = 0.98). Conclusions: While outcomes of combined HCC-CC are poor and optimal treatment remains undefined, TARE appears to represent an effective locoregional treatment with survival outcomes similar to that of HCC treated by TARE.
Gastrointest Tumors

中文翻译：

---

钇90放射栓塞治疗联合肝细胞和胆管癌

目的：在倾向匹配研究中报告使用玻璃微球治疗混合肝细胞胆管癌 (HCC-CC) 的经动脉放射栓塞 (TARE) 的结果。材料和方法：在 2013 年至 2019 年期间，连续 10 名组织学证实为 HCC-CC 的患者接受了使用玻璃微球作为主要初始治疗的目标区域的 TARE。除肿瘤分布、Child Pugh 评分和 BCLC 外，还记录了基线人口统计数据。根据修改后的 RECIST 标准评估肿瘤反应。HCC-CC 队列与 HCC 队列相匹配，并进行了客观反应和生存分析。结果：在 HCC-CC 队列中，患者的客观缓解率 (ORR) 为 70%，而在 HCC 队列中，匹配后患者的 ORR 为 90% ( p = 0.54)。在匹配人群中，HCC 患者的中位总生存期（OS）为 12.3 个月（95% CI：6.0-17.4 个月），而 HCC-CC 患者的中位 OS 为 15.2 个月（95% CI：2.7-20.2 个月） ) ( p = 0.98)。在匹配人群中，HCC 患者的中位无进展生存期 (PFS) 为 11.6 个月 (95% CI: 2.53–19.3 个月)，而 HCC-CC 患者的中位 PFS 为 15.2 个月 (95% CI: 2.7– 20.2 个月) ( p= 0.94)。在匹配人群中，HCC 患者的中位无移植生存期 (TFS) 为 12.3 个月 (95% CI: 6.0–17.4 个月)，而 HCC-CC 患者的中位 TFS 为 15.2 个月 (95% CI: 2.7– 20.2 个月）（p = 0.98）。结论：虽然联合 HCC-CC 的结果很差，最佳治疗仍未确定，但 TARE 似乎代表了一种有效的局部区域治疗，其生存结果与 TARE 治疗的 HCC 相似。
胃肠肿瘤